Home » Market News » DirectorsTalk Highlights » Shaping the Future of Cancer Therapy
Avacta Group Plc

Shaping the Future of Cancer Therapy

A New Approach is Needed

Avacta has two proprietary therapeutic platforms positioning the company uniquely well to address the gap in cancer immunotherapies

Affimer – Alternative to anti-bodies

  • 10x smaller than antibodies
  • 10x cheaper to manufacture
  • Easier to modify and develop

TMAC – Targeted chemotherapy

  • Tumour targeted release of chemo
  • Reduced side effects
  • Longer and greater dosing

Avacta Group Plc (LON:AVCT) offers reagents and therapeutics based on Affimer technology for diagnostic and research applications in the United Kingdom. The company’s custom Affimer products are also used in drugs and biomarkers discovery in biotech research and development.

To read the full news article please click here

Receive our exclusive interviews – Enter your email to stay up to date.

Disclaimer: Statements in this article should not be considered investment advice, which is best sought directly from a qualified professional.